



# Kent Academic Repository

Frost, Rachael, Bhamra, S.K. and Heinrich, Michael (2026) *Herbal products and antidepressants: a safe combination or a risky mix?* *Phytotherapy Research*, 40 (3). pp. 941-948. ISSN 0951-418X.

## Downloaded from

<https://kar.kent.ac.uk/112766/> The University of Kent's Academic Repository KAR

## The version of record is available from

<https://doi.org/10.1002/ptr.70173>

## This document version

Author's Accepted Manuscript

## DOI for this version

## Licence for this version

CC BY (Attribution)

## Additional information

## Versions of research works

### Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

### Author Accepted Manuscripts

If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in **Title of Journal**, Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

### Enquiries

If you have questions about this document contact [ResearchSupport@kent.ac.uk](mailto:ResearchSupport@kent.ac.uk). Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our [Take Down policy](https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies) (available from <https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies>).

## **Herbal products and antidepressants: a safe combination or a risky mix?**

Rachael Frost<sup>1\*</sup>, Sukvinder Kaur Bhamra<sup>2</sup>, Michael Heinrich<sup>3,4</sup>

<sup>1</sup>School of Public and Allied Health, Liverpool John Moores University, Liverpool, UK.

<sup>2</sup>Medway School of Pharmacy, University of Kent, Kent, UK.

<sup>3</sup>UCL School of Pharmacy, University College London, London, UK.

<sup>4</sup>China Medical University, Taichung, Taiwan.

\*corresponding author. Dr Rachael Frost, School of Public and Allied Health, Liverpool John

Moores University, Tithebarn Building, 79 Tithebarn Street, Liverpool, L2 2ER. Email:

[r.h.frost@ljmu.ac.uk](mailto:r.h.frost@ljmu.ac.uk)

One in five adults in England has a common mental health condition, most commonly Generalised Anxiety Disorder (GAD) (7.5%) and depression (3.8%), and these are most frequently treated with prescribed medication (51.8% and 46.7%, respectively). Surveys estimate that concurrent use of herbal products and medication for psychological conditions ranges from 12-27.5% [1,2]. This raises safety concerns – for example, St John’s Wort is contraindicated alongside selective serotonin reuptake inhibitors (SSRIs) due to similar mechanisms that increase the risk for serotonin syndrome. However, other herb-drug safety data is generally limited, and providing further evidence on this is vital for patient and clinician decision making.

We recently reviewed over-the-counter (OTC) products for anxiety, depression and insomnia in all age groups of adults and older adults [3–6]. Review searches were carried out in MEDLINE, Embase, PsycINFO, AMED, and CENTRAL (inception-Dec 2022) and included 404 randomised controlled trials (RCTs) of herbal products, dietary supplements, medications and homeopathic products, administered to adults for  $\geq 1$  week with symptoms or a diagnosis of depression, anxiety and/or insomnia. We found a wide range of products were tested. This letter reports on a closer analysis of the safety of herbal products, specifically those that were tested as adjunct therapies to prescribed antidepressant treatment compared a control treatment plus the antidepressant, and reported upon adverse events.

Out of the 163 herbal product RCTs, 17 were evaluated as adjuncts to antidepressants and reported data regarding adverse events (Table 1). Most studies were in people with a depression diagnosis (n=10) or anxiety diagnosis (n=4). Two were in people with a health condition plus depressive symptoms and one was in people with mild-moderate depressive symptoms.

Herbal products assessed included saffron/crocin (n=4) [7–10], curcumin (n=2) [11,12], and one each of rhodiola [13], cinnamon [14], black seed [15], passionflower [16], Echium [17], lavender [18], rosemary [19], ashwagandha [20], ginkgo [21] and St John’s Wort [22]. Two combination

products were included (saffron, St John's Wort, cinnamon and grape juice [23]) and saffron plus curcumin [12]. Duration of use was 4-12 weeks. Most products were administered alongside SSRIs (n=13), reflecting current prescribing trends, mainly sertraline (n=5), with a small number of other drug types. Two studies assessed adjunctive treatment alongside usual antidepressants (taken by 42-64% patients [12]) or all patients [10]. Eleven studies reported that there were no serious adverse events (SAEs), whilst six discussed only adverse events (AEs), implying but not clearly stating a lack of SAEs.

Saffron and crocin (an extract from saffron) showed few safety issues, with no significant differences in AEs adjunctively to fluoxetine [8], mixed SSRIs [9] and mixed antidepressants [10] at 28-30mg/day. Where details were reported [7,9], these were mild (see Table 1). At higher doses (450mg/day), there were mild AEs alongside sertraline but placebo group AEs were not reported [7]. Curcumin (1000mg/day) alongside escitalopram produced mild nausea (frequency not reported) but otherwise no safety issues compared to placebo [11]. Alongside mixed antidepressants in a four-arm trial, there were no differences according to dosage or with a saffron-curcumin product, apart from high doses (1000mg/day) producing a higher frequency of diarrhoea [12].

Rhodiola and ginkgo appeared to have protective effects. Significantly fewer rhodiola patients reported AEs alongside sertraline than placebo, particularly at higher doses [13], whilst fewer AEs (significance not reported) occurred from ginkgo alongside venlafaxine than venlafaxine alone [21]. Similarly, alongside a combination of mixed tricyclic antidepressants, St John's Wort showed better quality sleep, fewer GI complications and increased energy. Photosensitivity was noted in three patients but managed using sunscreen [22].

Alongside sertraline, no complications were reported for black seed [15]. Cinnamon capsules and passionflower drops showed no significant differences in AE frequency vs placebo [14,16], but nausea and dizziness was higher in the passionflower group [16]. Echium plus fluoxetine

showed no significant differences compared to placebo, with the most common side effect being headache [17]. Alongside citalopram, lavender tea showed no significant differences in side effects vs citalopram alone, although nausea was more common in the lavender group, dry mouth in the citalopram group and confusion was common in both [18]. A combination product (saffron, St John's Wort, cinnamon and grape juice syrup) showed no serious adverse events alongside SSRIs maintained at a stable dose, with individual AEs not reported [23].

Alongside mixed SSRIs, ashwagandha showed no significant differences in side effects vs placebo, with only rare ones reported [20]. Rosemary however showed significantly higher rates of heart burn and increased memory alongside mixed SSRIs, and non-significantly higher nausea, constipation and drowsiness but lower levels of diarrhoea [19].

This analysis is limited by the small subset of studies that reported safety data, and even these were reported in variable detail. Trials mainly had small sample sizes and are likely underpowered for detecting AE differences. In a few studies antidepressants were used by the majority, but not all, of the sample. Reporting of manufacturing and quality control procedures was variable – in cases of safety it is essential this is clearly reported to ensure that product safety (or lack of) is not due to adulteration, poor quality or a lack of active metabolites or marker compounds, particularly given that many herbal products are not regulated as medicines [24].

Most products evaluated alongside antidepressants in this analysis showed few concerns regarding interactions, and some products may even mitigate antidepressant side effects. Studies need to assess longer term usage and more clearly report AE frequencies and types in both arms. Authors are also encouraged to follow the ConPhyMP reporting checklist [25] to report sourcing, processing, composition and quality assurance of plant extracts, to better inform future safety and effectiveness studies.

## References

- [1] Niv N, Shatkin JP, Hamilton AB, Unützer J, Klap R, Young AS. The Use of Herbal Medications and Dietary Supplements by People with Mental Illness. *Community Ment Health J* 2010;46:563–9. <https://doi.org/10.1007/s10597-009-9235-2>.
- [2] McIntyre E, Saliba AJ, Wiener KK, Sarris J. Herbal medicine use behaviour in Australian adults who experience anxiety: a descriptive study. *BMC Complement Altern Med* 2016;16:60. <https://doi.org/10.1186/s12906-016-1022-3>.
- [3] Frost R, Mathew S, Thomas V, Uddin S, Salame A, Vial C, et al. A scoping review of over-the-counter products for depression, anxiety and insomnia in older people. *BMC Complement Med Ther* 2024;24:275. <https://doi.org/10.1186/s12906-024-04585-0>.
- [4] Frost R, Zamri A, Mathew S, Salame A, Bhanu C, Bhamra SK, et al. Understanding the research landscape of over-the-counter herbal products, dietary supplements, and medications evaluated for depressive symptoms in adults: a scoping review. *Front Pharmacol* 2025;16:1609605. <https://doi.org/10.3389/fphar.2025.1609605>.
- [5] Frost R, Uddin S, Mathew S, Thomas V, Salame A, Bhamra SK, et al. What over the counter (OTC) products have been evaluated for anxiety in adults aged 18–60? A scoping review. *Journal of Mental Health* 2024:1–21. <https://doi.org/10.1080/09638237.2024.2408231>.
- [6] Salame A, Mathew S, Bhanu C, Bazo-Alvarez JC, Bhamra SK, Heinrich M, et al. Over-the-counter products for insomnia in adults: A scoping review of randomised controlled trials. *Sleep Medicine* 2025;129:219–37. <https://doi.org/10.1016/j.sleep.2025.02.027>.
- [7] Jafarnia N, Ghorbani Z, Nokhostin M, Manayi A, Nourimajd S, Razeghi Jahromi S. Effect of Saffron (*Crocus Sativus* L.) as an Add-On Therapy to Sertraline in Mild to Moderate Generalized Anxiety Disorder: A Double Blind Randomized Controlled Trial. *Arch Neurosci* 2017;In Press. <https://doi.org/10.5812/archneurosci.14332>.
- [8] Jelodar G, Javid Z, Sahraian A, Jelodar S. Saffron improved depression and reduced homocysteine level in patients with major depression: A Randomized, double-blind study 2018;8.
- [9] Talaei A, Hassanpour Moghadam M, Sajadi Tabassi SA, Mohajeri SA. Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: A randomized, double-blind, placebo-controlled, pilot clinical trial. *Journal of Affective Disorders* 2015;174:51–6. <https://doi.org/10.1016/j.jad.2014.11.035>.
- [10] Lopresti AL, Smith SJ, Hood SD, Drummond PD. Efficacy of a standardised saffron extract (affron®) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: A randomised, double-blind, placebo-controlled study. *J Psychopharmacol* 2019;33:1415–27. <https://doi.org/10.1177/0269881119867703>.
- [11] Yu J-J, Pei L-B, Zhang Y, Wen Z-Y, Yang J-L. Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. *Journal of Clinical Psychopharmacology* 2015;35:406–10. <https://doi.org/10.1097/JCP.0000000000000352>.
- [12] Lopresti AL, Drummond PD. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind,

- placebo-controlled study. *Journal of Affective Disorders* 2017;207:188–96.  
<https://doi.org/10.1016/j.jad.2016.09.047>.
- [13] Gao L, Wu C, Liao Y, Wang J. Antidepressants effects of Rhodiola capsule combined with sertraline for major depressive disorder: A randomized double-blind placebo-controlled clinical trial. *Journal of Affective Disorders* 2020;265:99–103. <https://doi.org/10.1016/j.jad.2020.01.065>.
- [14] Ghaffari S, Ghobadi A, Jamshidi AH, Mortazavi SH, Naderi S, Aqamolaei A, et al. Cinnamomum tamala as an adjuvant therapy in the treatment of major depressive disorder: A double-blind, randomized, placebo-controlled clinical trial with placebo control. *Advances in Integrative Medicine* 2020;7:141–7.  
<https://doi.org/10.1016/j.aimed.2019.12.002>.
- [15] Rafiee Zadeh A, Foroughi Eghbal A, Mirghazanfari S, Ghasemzadeh M, Nassireslami E, Donyavi V. Nigella sativa extract in the treatment of depression and serum Brain-Derived Neurotrophic Factor (BDNF) levels. *J Res Med Sci* 2022;27:28.  
[https://doi.org/10.4103/jrms.jrms\\_823\\_21](https://doi.org/10.4103/jrms.jrms_823_21).
- [16] Nojoudi M, Ghaeli P, Salimi S, Sharifi A, Raisi F. Effects of Passion Flower Extract, as an Add-On Treatment to Sertraline, on Reaction Time in Patients with Generalized Anxiety Disorder: A Double-Blind Placebo-Controlled Study 2016.
- [17] Sayyah M, Siahpoosh A, Khalili H, Malayeri A, Samaee H. A Double-Blind, Placebo-Controlled Study of the Aqueous Extract of Echium amoenum for Patients with General Anxiety Disorder 2012.
- [18] Nikfarjam M, Parvin N, Assarzadegan N, Asghari S. The Effects of Lavandula Angustifolia Mill Infusion on Depression in Patients Using Citalopram: A comparison Study. *Iran Red Crescent Med J* 2013;15:734–9.  
<https://doi.org/10.5812/ircmj.4173>.
- [19] Azizi S, Mohamadi N, Sharififar F, Dehghannoudeh G, Jahanbakhsh F, Dabaghzadeh F. Rosemary as an adjunctive treatment in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. *Complementary Therapies in Clinical Practice* 2022;49:101685. <https://doi.org/10.1016/j.ctcp.2022.101685>.
- [20] Fuladi S, Emami SA, Mohammadpour AH, Karimani A, Manteghi AA, Sahebkar A. Assessment of the Efficacy of Withania somnifera Root Extract in Patients with Generalized Anxiety Disorder: A Randomized Double-blind Placebo- Controlled Trial. *CRCEP* 2021;16:191–6.  
<https://doi.org/10.2174/1574884715666200413120413>.
- [21] Liang Z-H, Jia Y-B, Wang M-L, Li Z-R, Li M, Yun Y-L, et al. Efficacy of ginkgo biloba extract as augmentation of venlafaxine in treating post-stroke depression. *NDT* 2019;Volume 15:2551–7. <https://doi.org/10.2147/NDT.S215191>.
- [22] Pakseresht S, Boustani H, Azemi ME, Nilsaz J, Babapour R, Haghdust MR. Evaluation of Pharmaceutical Products of St. John's Wort Efficacy Added on Tricyclic Antidepressants in treating Major Depressive Disorder: A Double Blind Randomized Control Trial. *Jundishapur J Nat Pharm Prod* 2012;7:106–10.  
<https://doi.org/10.17795/jjnpp-4318>.
- [23] Adalat M, Khalili M, Ayromlou H, Haririan S, Fazljou SMB, Rezaeizadeh H, et al. Antidepressant Effects of a Persian Medicine Remedy on Multiple Sclerosis Patients: A Double-Blinded Randomized Clinical Trial. *GMJ* 2019;8:e1212.  
<https://doi.org/10.31661/gmj.v8i0.1212>.

- [24] Orhan N, Gafner S, Blumenthal M. Estimating the extent of adulteration of the popular herbs black cohosh, echinacea, elder berry, ginkgo, and turmeric – its challenges and limitations. *Nat Prod Rep* 2024;41:1604–21.  
<https://doi.org/10.1039/D4NP00014E>.
- [25] Heinrich M, Jalil B. From the CONSORT to the ConPhyMP statement and beyond—how to ascertain best practice. *Front Pharmacol* 2023;14:1338710.  
<https://doi.org/10.3389/fphar.2023.1338710>.